Dusigitumab
Dusigitumab is an experimental drug that is currently under investigation for its potential use in the treatment of various cancer types. It is a type of monoclonal antibody that is designed to target and bind to specific proteins on the surface of cancer cells, thereby inhibiting their growth and proliferation.
Mechanism of Action[edit | edit source]
Dusigitumab works by binding to a specific protein on the surface of cancer cells known as HER2/neu. This protein is overexpressed in certain types of cancer, including breast cancer and ovarian cancer, and is associated with aggressive disease and poor prognosis. By binding to HER2/neu, dusigitumab is thought to inhibit the growth and proliferation of cancer cells that overexpress this protein.
Clinical Trials[edit | edit source]
Several clinical trials have been conducted to evaluate the safety and efficacy of dusigitumab in the treatment of various cancer types. These trials have shown promising results, with some patients experiencing significant reductions in tumor size and improved survival rates. However, further research is needed to fully understand the potential benefits and risks of this treatment.
Side Effects[edit | edit source]
Like all drugs, dusigitumab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and diarrhea. Less common but more serious side effects can include infusion reactions, heart problems, and lung problems. Patients should discuss these potential risks with their healthcare provider before starting treatment with dusigitumab.
Future Directions[edit | edit source]
Research is ongoing to further evaluate the potential benefits and risks of dusigitumab in the treatment of various cancer types. Future studies may also explore the use of this drug in combination with other treatments, such as chemotherapy or radiation therapy, to enhance its effectiveness.
| Dusigitumab Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
